Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
17.05 USD | -0.18% | +2.03% | -45.54% |
Apr. 30 | UBS Adjusts ACADIA Pharmaceuticals' Price Target to $27 From $33, Keeps Buy Rating | MT |
Apr. 23 | Neuren Pharmaceuticals' Medication Secures Priority Review from Health Canada | MT |
Financials (USD)
Sales 2024 * | 966M | Sales 2025 * | 1.08B | Capitalization | 2.82B |
---|---|---|---|---|---|
Net income 2024 * | 110M | Net income 2025 * | 221M | EV / Sales 2024 * | 2.29 x |
Net cash position 2024 * | 606M | Net cash position 2025 * | 860M | EV / Sales 2025 * | 1.81 x |
P/E ratio 2024 * |
27.2
x | P/E ratio 2025 * |
13.2
x | Employees | 598 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.46% |
Latest transcript on ACADIA Pharmaceuticals Inc.
1 day | -0.18% | ||
1 week | +2.03% | ||
Current month | +2.03% | ||
1 month | -7.44% | ||
3 months | -32.58% | ||
6 months | -29.16% | ||
Current year | -45.54% |
Managers | Title | Age | Since |
---|---|---|---|
Stephen Davis
CEO | Chief Executive Officer | 63 | 14-07-14 |
Mark Schneyer
DFI | Director of Finance/CFO | 50 | 20-05-27 |
Benir Ruano
CTO | Chief Tech/Sci/R&D Officer | - | 22-10-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Julian Baker
BRD | Director/Board Member | 57 | 15-12-10 |
Edmund Harrigan
BRD | Director/Board Member | 71 | 15-11-24 |
Stephen Davis
CEO | Chief Executive Officer | 63 | 14-07-14 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
3.73% | 1 M€ | -4.80% | - | |
1.24% | 16 M€ | -4.51% | ||
0.26% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-03 | 17.05 | -0.18% | 1,160,279 |
24-05-02 | 17.08 | +0.18% | 1,611,684 |
24-05-01 | 17.05 | +2.03% | 1,627,841 |
24-04-30 | 16.71 | -2.28% | 1,307,642 |
24-04-29 | 17.1 | +2.33% | 1,887,790 |
Delayed Quote Nasdaq, May 03, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-45.54% | 2.82B | |
+25.69% | 47.86B | |
+46.90% | 41.42B | |
-3.46% | 40.66B | |
-6.20% | 28.92B | |
+9.17% | 25.55B | |
-20.42% | 19.27B | |
+0.17% | 12.15B | |
+28.07% | 12.14B | |
-1.24% | 11.99B |
- Stock Market
- Equities
- ACAD Stock